Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.

Abstract: Compositions and methods for reducing inflammation in the central nervous system (CNS) of a mammal that has been subjected to a stroke, traumatic injury to the CNS such as traumatic brain injury (TBI), spinal cord injury (SCI), or having an autoimmune or CNS disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., ASC, NALP1) in a mammalian inflammasome (e.g., the NALP1 inflammasome) and have use as treatments for SCI, TBI, stroke, and autoimmune and CNS diseases in a mammal. In a rodent model of SCI, therapeutic neutralization of ASC using a polyclonal antibody that specifically binds to ASC inhibited the inflammasome, reduced caspase-1 activation, XIAP cleavage, and interleukin processing, resulting in significant tissue sparing and functional improvement. Additionally, in a rodent model of TBI, neutralization of ASC after TBI reduced caspase-1 activation and XIAP cleavage.

Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.

Abstract: Antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.

Abstract: The present invention relates to therapeutic agents comprising bispecific recombinant antibody fragments to selectively clear a protein associated with a neurological disease and methods of use of these therapeutic agents to treat neurological diseases.

Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen.

Abstract: The instant invention relates to the field of protein production and in particular to controlled protein heterogeneity compositions and processes for controlling the heterogeneity of proteins expressed in host cells.

Abstract: The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent.

Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.

Abstract: The present invention relates generally to antibodies cross-reactive with IL-17A and IL-17F, and bispecific anti-IL-17A/F and their uses.

Abstract: Alleviating neural injury, such as spinal cord injury, in a subject (e.g., a human subject) in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.

Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.

Abstract: The present invention relates to antibodies against angiopoietins 1 and 2, and derivatives of these antibodies. More specifically, the present invention relates to therapeutic use of the antibodies and fragment thereof which specifically bind to angiopoietins 1 and 2.

Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

Abstract: The application provides methods of detection, diagnosis, prognosis, prophylaxis and treatment of folate receptor-alpha-expressing gastric cancer using antibodies that specifically bind to folate receptor alpha.

Abstract: Provided herein are methods for reducing, inhibiting, suppressing and/or delaying atherosclerotic plaque growth or neovascularization in a subject having atherosclerosis, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to Semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

Abstract: The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg.

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

Abstract: The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.

Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.

Abstract: Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium.

Abstract: The disclosure relates to a polypeptide comprising at least four domains specifically binding to a certain MHC peptide complex, the domains separated by linker amino acid sequences, thereby providing each domain with the capability to bind a separate MHC peptide complex, to a nucleic acid encoding for such a polypeptide, to a vector comprising such a nucleic acid, to a host cell for expression of such a polypeptide, to a pharmaceutical composition comprising such a polypeptide, and to a kit of parts comprising at least two polypeptides according to the disclosure.

Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.

Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

Abstract: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.

Abstract: The present invention relates to an antibody being capable of binding specifically to BC200 RNA or its antigen binding fragment, a polynucleotide of encoding the antibody or its antigen binding fragment, a composition, kit and method for detecting BC200 RNA in a sample using the antibody or its antigen binding fragment, and a composition for diagnosis, prevention or treatment of BC200 RNA-associated diseases including the antibody or its antigen binding fragment.

Abstract: The present invention relates to amino acid sequences that are directed against G-protein coupled receptors (GPCRs), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.

Abstract: A method of inhibiting the growth of bacteria in an absorbent device by using kraft pulp fiber subjected to an acidic, catalyzed peroxide treatment process incorporated into a single stage of a multi-stage bleaching process.

Abstract: A cellulose resin produced by binding cardanol or a derivative thereof to cellulose or a derivative thereof with the use of a cellulose hydroxy group of the cellulose or a derivative thereof and the phenolic hydroxy group of the cardanol or a derivative thereof.

Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.

Abstract: The present invention relates to water and solvent-free polymers, in particular water and solvent-free synthetic rubber products like non-halogenated and halogenated butyl rubber products as well as a process for the production thereof. The invention further relates to a device suitable to accomplish said process.

Abstract: The present invention relates to a new and efficient toxicity and/or odor reducing method for ethyl acrylate and/or acrylonitrile contained aqueous polymer dispersion.

Abstract: The embodiments of the invention provide a polymerizable oligomer and a photoresist composition including the polymerizable oligomer, wherein the polymerizable oligomer contains a polymerizable double bond and a hydrophilic group.

Abstract: A method can be used to provide electrically-conductive articles with electrolessly plated metal, or articles having antimicrobial properties for marine environments. The method includes disposing a silver-containing composition onto one or more supporting sides of a substrate such as continuous polymeric web. The silver-containing composition comprises a water-soluble complex of a reactive polymer with reducible silver ions, the reactive polymer comprising: (a) greater than 1 mol % of recurring units comprising sulfonic acid or sulfonate groups, (b) at least 5 mol % of recurring units comprising a pendant group capable of crosslinking via [2+2] photocycloaddition, and optionally (c) at least 1 mol % of recurring units comprising a pendant amide, hydroxyl, lactam, phosphonic acid, or carboxylic acid group. The reducible silver ions can be suitably reduced and the reactive polymer can be photoexposed to provide crosslinking in patternwise or uniform fashion.

Abstract: The invention relates to a process for preparing a polymerization catalyst component wherein a solid compound with formula Mg(OR1)xCl2-x wherein x is larger than 0 and smaller than 2, and each R1, independently, represents an alkyl group, said compound being obtained by reacting a Grignard compound with an alkoxy- or aryloxy-containing silane compound, is contacted with at least one activating compound selected from the group formed by internal electron donors and compounds of formula M(OR2)v-w(R3)w, wherein M can be Ti, Zr, Hf, Al or Si, each R2 and R3, independently, represent an alkyl, alkenyl or aryl group, v is the valency of M and w is smaller than v, in the presence of an inert dispersant to give an intermediate reaction product, and wherein the intermediate reaction product is contacted with a halogen-containing Ti-compound. A catalyst system comprising said component shows improved performance in olefin polymerization.

Abstract: A process includes preparing a diluted catalyst slurry in a catalyst slurry preparation system. The diluted catalyst slurry contains solid particulate catalyst and liquid hydrocarbon diluent. The catalyst slurry preparation system includes a mixing vessel with a top part, a bottom part and a rotatable impeller system which is actuated by a motor. The rotatable impeller system has a magnetic actuated agitator shaft which is positioned along a longitudinal axis of the mixing vessel and extends through the top part of the mixing vessel. At least two double-bladed hubs are fixed to the magnetic actuated agitator shaft.

Abstract: A process for the preparation of a polypropylene in a sequential polymerization process including a pre-polymerization reactor and at least two polymerization reactors connected in series. The polymerization in the at least two polymerization reactors takes place in the presence of a Ziegler-Natta catalyst. The Ziegler-Natta catalyst includes (a) a pro-catalyst that has a compound of a transition metal, a compound of a metal which metal is selected from one of the groups 1 to 3 of the periodic table (IUPAC), and an internal electron donor, (b) a co-catalyst, and (c) an external donor. The Ziegler-Natta catalyst is present in the pre-polymerization reactor. Ethylene and propylene are fed to the pre-polymerization reactor in a feed rate ratio of 0.5 to 10.0 g/kg.

Abstract: The purpose of the present invention is to provide a polymer having a low halogen atom content remaining in the polymer, a simple production method thereof, an active energy ray-curable composition that can be rapidly cured by an irradiation of a small amount of light, and a cured product thereof. These purpose can be achieved by an active energy ray-curable composition, including a polyisobutylene polymer (A) represented by the following general formula (1) (wherein R1 represents a monovalent or polyvalent aromatic hydrocarbon group, or a monovalent or a polyvalent aliphatic hydrocarbon group; A represents a polyisobutylene polymer; R2 represents a divalent saturated hydrocarbon group having 2-6 carbon atoms, which contains no hetero atoms; R3 and R4 each represent hydrogen, a monovalent hydrocarbon group having 1-20 carbon atoms, or an alkoxy group having 1-20 carbon atoms; R5 represents hydrogen or a methyl group; and n denotes a natural number), and an active energy ray polymerization initiator (B).

Abstract: A chain transfer agent composition comprises at least one branched C10 mercaptan selected from 5-methyl-1-mercapto-nonane, 3-propyl-1-mercapto-heptane, 4-ethyl-1-mercapto-octane, 2-butyl-1-mercapto-hexane, 5-methyl-2-mercapto-nonane, 3-propyl-2-mercapto-heptane, 4-ethyl-2-mercapto-octane, 5-methyl-5-mercapto-nonane, or combinations thereof. The chain transfer agent composition can be a component of an emulsion polymerization mixture and can be used in a process for emulsion polymerization for the production of polymers, for example, via free-radical polymerization.

Abstract: The present invention pertains to bio-based block polymers synthesized from functionalized lignin-based molecules (A-monomer) and functionalized fatty acids or fatty alcohols (B-monomer) derived from plant or animal oils, waxes or fats. The block polymers can be synthesized via numerous polymerization techniques, such as reversible addition-fragmentation chain transfer (RAFT). Most importantly, this class of bio-based block polymers shows promise as providing sustainable yet scalable and tunable thermoplastic elastomers and pressure-sensitive adhesives, among other applications.

Abstract: The disclosure discloses initiating systems for the radical polymerization of alkenes, and especially fluorine substituted alkenes. The polymerization is catalyzed by a metal carbonyl, preferably manganese carbonyl. The polymerization is initiated directly from alkyl halides at room temperature under visible white light. The polymers also allow the synthesis of block copolymers. The process comprises polymerizing at least one alkene monomer in the presence of a halide radical initiator, carbonyl catalyst and a solvent, under reaction conditions and for a time sufficient to polymerize the at least one alkene monomer to form a polymer. The present disclosure provides a method for living polymerization of alkene monomers which provides a high level of macromolecular control over the polymerization process and which leads to uniform and controllable polymeric products.

Abstract: The present invention relates to: a polymerizable compound (I), wherein Y1 to Y6 are a chemical single bond, —O—C(?O)—, —C(?O)—O— or the like, G1 and G2 are a divalent aliphatic group, Z1 and Z2 are an alkenyl group, Ax is a fused ring group represented by a formula (II), wherein X is —NR3—, an oxygen atom, a sulfur atom or the like, R3 is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and D is a substituted or unsubstituted ring having 1 to 20 carbon atoms that includes at least one nitrogen atom, Ay is a hydrogen atom, an alkyl group, A1 is a trivalent aromatic group or the like, A2 and A3 are a divalent aromatic group having 6 to 30 carbon atoms or the like, and Q1 is a hydrogen atom, or an alkyl group having 1 to 6 carbon atoms.

Abstract: A bis-imine complex of lanthanides having general formula (I): Said bis-imine complex of lanthanides having general formula (I) can be advantageously used in a catalytic system for the (co)polymerization of conjugated dienes.

Abstract: The present invention relates to a polypropylene composition comprising comonomer units derived from ethylene in an amount of from 0.5 wt % to 25 wt %, and from at least one C5-12 alpha-olefin in an amount of from 1.0 mol % to 3.0 mol %, wherein the polypropylene composition has an amount of xylene solubles XS of at least 20 wt %, and the xylene solubles have an amount of ethylene-derived comonomer units of from 4 wt % to 50 wt %.

Abstract: A process for the production of ethylene alpha-olefin copolymers is disclosed. The process may include feeding a catalyst system comprising a supported metallocene, such as a hafnocene, having pores saturated with a selected liquid agent, to a gas phase polymerization reactor. Ethylene and an alpha-olefin may then be contacted with the supported metallocene in the gas phase polymerization reactor to produce an ethylene alpha-olefin copolymer. The copolymer may have a density of less than 0.93 g/cm3, a melt index (I2) of less than 2 dg/min, and a melt flow ratio (I21/I2) of at least 28. To advantageously result in desired effects on catalyst properties and/or polymer properties, the liquid agent may be selected to advantageously manipulate catalyst temperature profiles and/or catalyst-monomer interaction during an initial heating period when the catalyst is first introduced to the reactor.

Abstract: Provided are vinylidene fluoride copolymers exhibiting higher adhesion with respect to metal foils than do conventional vinylidene fluoride copolymers, and to provide uses of the vinylidene fluoride copolymers. The vinylidene fluoride copolymers are obtained by copolymerizing vinylidene fluoride with a compound represented by Formula (A). In Formula (A), R1, R2 and R3 are each independently a hydrogen atom, a chlorine atom or an alkyl group; and X is an atomic group with a molecular weight of not more than 500 containing a heteroatom and having a main chain composed of 1 to 20 atoms, or is a heteroatom.

Abstract: This invention pertains to a novel fluoropolymer characterized by a dichloroamino-functionalized perfluoroether pendant group that terminates in —CF2NCl2. The polymer so formed is crosslinkable and useful for the preparation of shaped articles and photo-imaged coatings. The novel fluoropolymer can be thermally treated to form crosslinked fluoropolymers with highly stable perfluoroalkylene crosslinks. The novel fluoropolymer is conveniently prepared by treating a cyano-functionalized fluoropolymer with Cl—F.

Abstract: A phenolic-type phosphorous curing agent works by grafting a phosphorous compound onto a benzene ring to substitute hydrogen atoms and is halogen-free and nonflammable; when acting with and curing an epoxy resin, the curing agent helps to form a higher crosslink density and excellent heat tolerance to let the epoxy resin suitable for use in making PCB's insulating layer or semiconductor packaging as well as to endow the PCB's insulating layer or semiconductor packaging provided with excellent flame retardance and high glass transition temperature (Tg).